Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Equity (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Return on Equity for 15 consecutive years, with 3.78% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 1236.0% to 3.78% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.78%, a 1236.0% increase, with the full-year FY2024 number at 0.08%, down 13.0% from a year prior.
  • Return on Equity was 3.78% for Q3 2025 at NovaBay Pharmaceuticals, up from 2.04% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 12.79% in Q2 2024 to a low of 8.58% in Q3 2024.
  • A 5-year average of 0.39% and a median of 0.27% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: soared 2774bps in 2021, then tumbled -1074bps in 2025.
  • NovaBay Pharmaceuticals' Return on Equity stood at 0.6% in 2021, then soared by 71bps to 0.17% in 2022, then tumbled by -334bps to 0.75% in 2023, then surged by 65bps to 0.26% in 2024, then soared by 1537bps to 3.78% in 2025.
  • Per Business Quant, the three most recent readings for NBY's Return on Equity are 3.78% (Q3 2025), 2.04% (Q2 2025), and 3.7% (Q1 2025).